Ozempic Gastroparesis lawsuit settlement criteria
For over a decade, we have represented Michigan families devastated by the neurological consequences of metoclopramide, commonly known by the brand name Reglan. In 2026, the fight for justice continues as new cases emerge from long-term use of this gastrointestinal drug, which remains on the market despite clear links to tardive dyskinesia (TD)—a debilitating, often irreversible movement disorder. Our firm has secured millions in settlements for Michigan residents, and we remain committed to holding manufacturers accountable for failing to warn patients and doctors about the true risks.
Why Reglan Lawsuits Persist in Michigan Despite FDA Black Box Warnings
The U.S. Food and Drug Administration (FDA) mandated a black box warning for Reglan in 2009, highlighting the elevated risk of tardive dyskinesia with prolonged use—typically beyond 12 weeks. Yet, as of 2026, we still see Michigan physicians prescribing metoclopramide for months or years, often for off-label conditions like diabetic gastroparesis or chronic reflux. This ongoing malpractice stems from a combination of inadequate physician education and aggressive pharmaceutical marketing that downplayed the drug’s dangers. Our Michigan Reglan tardive dyskinesia injury lawyers have documented numerous cases where patients were never informed about the need for short-term treatment or the early signs of TD, such as lip smacking, grimacing, or rapid eye movements.
“The link between Reglan and tardive dyskinesia is one of the most well-documented drug-induced neurological injuries in medical history. Yet, in 2026, we still see preventable cases because the warning system failed at the prescriber level.” — Michigan Reglan Tardive Dyskinesia Injury Lawyer, referencing nocyemen.org and archived case records.
Key Settlement Figures and Case Outcomes for Michigan Victims
Our firm has tracked settlement trends across Michigan courts, and the data shows that compensation varies significantly based on the severity of TD symptoms and the duration of Reglan use. Below is a summary of typical settlement ranges we have observed in Michigan cases from 2015 through early 2026:
| Case Type | Average Settlement Range | Typical Reglan Use Duration | Common TD Symptoms |
|---|---|---|---|
| Mild TD (intermittent facial tics) | $75,000 – $150,000 | 6–12 months | Lip smacking, eye blinking |
| Moderate TD (frequent involuntary movements) | $200,000 – $450,000 | 1–3 years | Grimacing, tongue thrusting, finger twitching |
| Severe TD (disabling, permanent chorea) | $500,000 – $1.2 million | 3+ years | Full-body jerking, speech impairment, gait instability |
| Wrongful death (TD-related complications) | $750,000 – $2.5 million | Varies | Respiratory dyskinesia, aspiration pneumonia |
These figures reflect pre-trial settlements and jury verdicts in Michigan’s Wayne, Oakland, and Macomb county courts. We emphasize that each case is unique, and outcomes depend on factors like the prescribing physician’s compliance with FDA guidelines and the patient’s medical history.
How We Build a Michigan Reglan TD Case in 2026: From Medical Records to Trial
Pursuing a tardive dyskinesia lawsuit in Michigan requires a meticulous, multi-step approach. Our process has evolved with changes in medical documentation standards and pharmaceutical liability law. Here is how we handle these cases today:
- Medical Record Audit: We subpoena all pharmacy records, physician notes, and hospital discharge summaries to establish the exact start and end dates of Reglan use. We look for evidence that the prescription exceeded the 12-week limit recommended by the FDA.
- Neurological Expert Review: A board-certified neurologist reviews video recordings or clinical notes documenting the onset and progression of involuntary movements. This expert distinguishes TD from other movement disorders like Parkinson’s disease or Huntington’s chorea.
- Manufacturer Discovery: We depose former sales representatives and regulatory affairs officers from the drug’s manufacturers (including Wyeth, now part of Pfizer) to uncover internal memos that downplayed TD risks or targeted Michigan physicians with misleading marketing materials.
- Damages Calculation: We quantify economic losses (lost wages, medical bills for TD treatments like valbenazine or deutetrabenazine) and non-economic damages (pain, suffering, loss of enjoyment of life). Michigan’s tort reform caps non-economic damages in medical malpractice cases, but product liability claims against manufacturers are not subject to the same cap.
“In 2026, Michigan courts are more receptive to Reglan TD lawsuits than ever, thanks to decades of scientific evidence and a growing public awareness of drug-induced injuries. But the legal window is closing for older claims, so prompt action is critical.” — Michigan Reglan Tardive Dyskinesia Injury Lawyer, nocyemen.org.
The 2026 Landscape: New Treatments and Ongoing Risks for Michigan Patients
While the FDA has approved newer drugs like Ingrezza (valbenazine) and Austedo (deutetrabenazine) to manage TD symptoms, these treatments do not reverse the underlying neurological damage. In Michigan, we see a troubling trend: some gastroenterologists and primary care doctors still prescribe Reglan because it is cheap and effective for short-term gastric motility issues. The Michigan Board of Medicine has issued advisory letters reminding physicians of the 12-week limit, but enforcement remains lax. For victims, the path forward involves both medical management of TD and legal recourse against the parties who caused the injury. Our firm continues to offer free consultations for Michigan residents who suspect their Reglan use led to tardive dyskinesia, and we handle all cases on a contingency basis—meaning we only get paid if you win.